Cover Image
市場調查報告書

全球膝關節軟骨修復市場上產品·開發平台分析

A Product and Pipeline Analysis of the Global Knee Cartilage Repair Market

出版商 Frost & Sullivan 商品編碼 314702
出版日期 內容資訊 英文 96 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球膝關節軟骨修復市場上產品·開發平台分析 A Product and Pipeline Analysis of the Global Knee Cartilage Repair Market
出版日期: 2014年09月19日 內容資訊: 英文 96 Pages
簡介

標準治療的微創手術並未滿足軟骨缺損患者的長期性需求。再加上現在的替代療法選擇正面臨複合性課題及限制之苦。

本報告以膝關節軟骨修復市場上之醫藥品為焦點,提供主要9項產品的詳細概要,全球,美國及歐洲市場已上市·實驗中的自體細胞療法,同種異體細胞療法及非細胞產品之產品·開發平台評估,彙整美國·歐洲預計現在或馬上投入市場的細胞再生療法之產品簡介及實行中臨床實驗相關分析,為您概述為以下內容。

第1章 摘要整理

第2章 市場概要

  • 市場定義
  • 市場機會
  • 市場概要
  • 目前膝關節軟骨治療選擇
  • 對3·4級膝軟骨缺損患者來說仍持續存在龐大的未滿足需求
  • 技術提升增加了產品公共事業
  • 市場成長的促進要素·阻礙要素
  • 近幾年的市場發展

第3章 全球競爭情形

  • 膝關節軟骨修復市場:主要產品的競爭情形
  • 主要的上市·開發中產品的差別化因素
  • 競爭情形:對主要產品來說極為重要的第三階段實驗
  • 競爭情形:對主要產品來說的上市後實驗
  • 全球主要產品的認證計劃預測
  • 主要產品的法規途徑

第4章 美國的競爭情形

  • 膝關節軟骨修復市場:全上市·開發中產品的美國競爭情形
  • 主要上市產品分析
  • 主要開發中產品分析
  • 競爭情形:極為重要的第三階段實驗
  • 競爭情形:極為重要的第三階段實驗詳細內容
  • 競爭情形:上市後實驗

第5章 歐洲的競爭情形

第6章 主要打入市場企業詳細內容評估

  • NeoCart
  • NovoCart 3D
  • RevaFlex
  • Carticel
  • MACI
  • ChondroCelect
  • DeNovo NT
  • Cartiform
  • BioCartilage
  • Cartistem

第7章 KOL(主要意見領袖)的洞察

第8章 結論

第9章 FROST & SULLIVAN

目錄
Product Code: NE07-01-00-00-00

A New Standard of Care May Be on the Horizon

The standard of care, microfracture, does not fulfill long-term needs for patients with chondral defects. In addition, current alternative treatment options are plagued by multiple challenges and limitations. This research service focuses on medicine in the knee cartilage repair market, providing a detailed overview of 9 key products. A product and pipeline assessment is provided for marketed and investigational autologous cell-based therapy, allogenic cell-based therapy, and non-cellular products in the global, US, and European markets. Product profiles are included for companies that are currently or imminently marketing cell-based regenerative therapies and conducting clinical trials in the United States and Europe.

Table of Contents

1. EXECUTIVE SUMMARY

  • 1. Key Findings
  • 2. Key Findings (continued)
  • 3. The Ideal Knee Chondral Defect Repair Solution
  • 4. Key Companies to Watch
  • 5. Other Companies to Watch

2. MARKET OVERVIEW

  • 1. Market Definitions
  • 2. Market Opportunity
  • 3. Market Overview
  • 4. Market Overview (continued)
  • 5. Market Overview (continued)
  • 6. Market Overview (continued)
  • 7. Market Overview (continued)
  • 8. Market Overview (continued)
  • 9. Market Overview (continued)
  • 10. Market Overview (continued)
  • 11. Current Cartilage Treatment Options
  • 12. Significant Unmet Need Continues to Exist for Patients with Grades 3 and 4 Knee Chondral Defects
  • 13. Technology Improvement Increases Product Utility
  • 14. Market Drivers and Restraints
  • 15. Recent Market Developments
  • 16. Recent Market Developments (continued)

3. GLOBAL COMPETITIVE LANDSCAPE

  • 1. Knee Cartilage Repair Market-Competitive Landscape of Key Products
  • 2. Knee Cartilage Repair Market-Competitive Landscape of Key Products (continued)
  • 3. Differentiators for Key Marketed and Pipeline Products
  • 4. Differentiators for Key Marketed and Pipeline Products (continued)
  • 5. Differentiators for Key Marketed and Pipeline Products (continued)
  • 6. Competitive Landscape-Pivotal Phase 3 Trials for Key Products
  • 7. Competitive Landscape-Post-marketed Trials for Key Products
  • 8. Global Estimated Approval Timelines for Key Products
  • 9. Regulatory Pathway for Key Products

4. US COMPETITIVE LANDSCAPE

  • 1. Knee Cartilage Repair Market-US Competitive Landscape of all Marketed and Pipeline Products
  • 2. Marketed Product Analysis of Key Products-US
  • 3. Pipeline Analysis of Key Products-US
  • 4. US Competitive Landscape-Pivotal Phase 3 Trials
  • 5. US Pivotal Phase 3 Trial Details
  • 6. US Competitive Landscape-Post-marketed Trials

5. EUROPE COMPETITIVE LANDSCAPE

  • 1. Knee Cartilage Repair Market-Europe Competitive Landscape of all Marketed Products
  • 2. Knee Cartilage Repair Market-Europe Competitive Landscape of all Pipeline Products
  • 3. Key Marketed Product Analysis-Europe
  • 4. Key Marketed Product Analysis-Europe (continued)
  • 5. Key Product Pipeline Analysis-Europe
  • 6. Europe Competitive Landscape-Pivotal Phase 3 Trials
  • 7. Europe Pivotal Phase 3 Trials
  • 8. Europe Pivotal Phase 3 Trials (continued)
  • 9. Europe Estimated Approval Timelines

6. DEEP DIVE ASSESSMENT OF KEY PARTICIPANTS

  • 1. NeoCart-Timelines for Focal Cartilage Defects
  • 2. NeoCart-Clinical Trial Design Approach and Key Published Data
  • 3. Product Dashboard-NeoCart
  • 4. NovoCart 3D-US Timelines for Focal Cartilage Defects
  • 5. NovoCart 3D-Europe Timelines for Focal Cartilage Defects
  • 6. NovoCart 3D-Clinical Trial Design Approach and Key Published Data
  • 7. NovoCart 3D-Clinical Trial Design Approach and Key Published Data (continued)
  • 8. Product Dashboard-NovoCart 3D
  • 9. RevaFlex-Timelines for Focal Cartilage Defects
  • 10. RevaFlex-Clinical Trial Design Approach and Key Published Data
  • 11. Product Dashboard-RevaFlex
  • 12. Carticel-Clinical Trial Design Approach and Key Published Data
  • 13. Carticel-Clinical Trial Design Approach and Key Published Data (continued)
  • 14. Product Dashboard-Carticel
  • 15. MACI-Clinical Trial Design Approach and Key Published Data
  • 16. MACI-Clinical Trial Design Approach and Key Published Data (continued)
  • 17. Product Dashboard-MACI
  • 18. ChondroCelect-Clinical Trial Design Approach and Key Published Data
  • 19. ChondroCelect-Clinical Trial Design Approach and Key Published Data (continued)
  • 20. Product Dashboard-ChondroCelect
  • 21. DeNovo NT-Clinical Trial Design Approach and Key Published Data
  • 22. DeNovo NT-Clinical Trial Design Approach and Key Published Data (continued)
  • 23. DeNovo NT-Clinical Trial Design Approach and Key Published Data (continued)
  • 24. Product Dashboard-DeNovo NT
  • 25. Product Dashboard-Cartiform
  • 26. Product Dashboard-BioCartilage
  • 27. Product Dashboard-Cartistem

7. KOL INSIGHTS

  • 1. Key Opinion Leader (KOL) Insights
  • 2. Key Opinion Leader (KOL) Insights (continued)

8. CONCLUSIONS

  • 1. Conclusions
  • 2. Legal Disclaimer

9. THE FROST & SULLIVAN STORY

  • 1. The Frost & Sullivan Story
  • 2. Value Proposition-Future of Your Company & Career
  • 3. Global Perspective
  • 4. Industry Convergence
  • 5. 360° Research Perspective
  • 6. Implementation Excellence
  • 7. Our Blue Ocean Strategy
Back to Top